CEO Today Global Awards

usa 57 www.ceotodaymagazine.com CEO Today Global Awards 2019 DOUG DOERFLER CEO of Maxcyte Inc FIRM PROFILE We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines. We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines. We are developing CARMA, our proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face significant challenges. We understand and scientifically solve partners’ challenges by applying our expertise and proven delivery platform for cell-engineering. At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use more cost-effectively and with lowered risk. Our broad intellectual property (IP) portfolio, along with our regulatory certifications and support, offer our partners both enhanced IP protection and broad freedom to operate. Scientists are just beginning to unravel the complexities of cells, their regulation, and their relationship to disease. As our understanding continues to grow, it reveals new avenues for therapeutic interventions and curative efforts. Cell-engineering looks to unlock the power of cells for a variety of applications including the discovery, development and manufacture of novel small molecule drugs and biologics, the biomanufacturing of vaccines and biotherapeutics, the re-direction or enhancement of cells for use as cellular therapies and the modification of targeted genes in cells for therapeutic purposes through genomic editing. We have developed and commercialized MaxCyte Scalable Transfection Systems for high- performance delivery of biomolecules using Flow Electroporation™ Technology, a proprietary cell- engineering technology designed to meet the stringent demands of clinical use – namely the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients. ABOUT DOUG DOERFLER Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, Chief Executive Officer and a director of Immunicon Corporation, a cell-based therapy and diagnostics company. He also held various executive positions with Life Technologies, Inc. that included leading its global businesses, mergers and acquisitions and its IPO. Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the Executive Committees of the Alliance for Regenerative Medicine and the Biotechnology Innovation Organization. Mr. Doerfler received his BS in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.